Dydrogesterone versus micronized vaginal progesterone for luteal phase support in artificial cycle frozen embryo transfer (REMODEL): a pilot prospective randomized controlled trial

Frontiers in Endocrinology 2026 Open access

Read full text
Authors: Caroline Roelens, Shari Mackens, Panagiotis Drakopoulos, Lisbet Van Landuyt, Michel De Vos, Herman J. Tournaye, Christophe Blockeel
DOI: 10.3389/fendo.2026.1785932
Cited by: 1
References: 33

Abstract

Background: The introduction of vitrification has markedly increased frozen embryo transfer (FET) cycles, driving efforts to optimize FET protocols. In artificial-cycle FET (AC-FET), micronized vaginal progesterone (MVP) is widely used for luteal phase support (LPS), though local side effects are common. Dydrogesterone (DYD), an oral selective progesterone receptor agonist, offers patient-friendly administration, but its efficacy in AC-FET remains uncertain. Methods: In this single-centre trial (October 2021 - September 2023), women

Fields of Study & Subjects

Ovarian function and disorders Reproductive Biology and Fertility Reproductive System and Pregnancy

Publication details

Journal / source
Frontiers in Endocrinology
Publisher
Frontiers Media SA
Volume
17
Pages
1785932–1785932
Publication date
16 April 2026
Language
EN